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Abstract: 
A novel fluorescein/Gd-DOTAGA containing nanoprobe for tumor visualization by Optical 
and Magnetic Resonance Imaging (MRI) is reported. It is based on the functionalization of 
small mesoporous silica nanoparticles (MSNs) (~30 nm) surface with the 
arginine-glycine-aspartic (RGD) moieties which are known to target v3 integrin receptors 
overexpressed in several tumor cells. The obtained nanoprobe (Gd-MSNs-RGD) displays good 
stability, tolerability and high relaxivity (37.6 mM
-1
s
-1
 at 21.5 MHz). After preliminary 
evaluation of the cytotoxicity and targeting capability toward U87MG cells by in vitro 
fluorescence and MR imaging, the nanoprobes were tested in vivo by acquiring T1-weighted MR 
imaging of xenografted murine tumor models. The obtained results demonstrated that the 
Gd-MSNs-RGD nanoprobes are good reporters both in vitro and in vivo, for the 
MR-visualization of tumor cells overexpressing v3 integrin receptors. 
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1 Introduction 
Magnetic resonance imaging (MRI) has gained a primary position in diagnostic clinical 
medicine and biomedical research because it provides highly spatially resolved images of soft 
tissues without the need to use ionizing radiation.
1
 In molecular imaging applications, MRI still 
suffers from a relatively low sensitivity of its probes, most of which are based on gadolinium 
complexes.
2
 Therefore, the development of highly efficient contrast agents (CAs) is currently a 
topic of great interest in many laboratories. The efficiency of a paramagnetic CA is first of all 
described by its relaxivity (the relaxation enhancement of solvent water protons brought by the 
presence of the relaxation enhancer at 1 mM concentration), r1, which depends on the structural, 
dynamic and electronic properties of the complex and its magnetic coupling with the solvent 
molecules.
3
 According to the Solomon-Bloembergen-Morgan theory, the increase in relaxivity 
of a Gd-based CA can be pursued by several routes, i.e., a greater number of inner-sphere water 
molecules, q; an optimally short residence lifetime, M, of the metal-coordinated water 
molecule(s); and a slow reorientational motion of the metal complex, R.
2, 4
 It was early shown 
that the latter task can be attained by immobilizing the Gd-CAs on nanostructured materials, 
thus slowing down their molecular tumbling but maintaining unaltered the water residence time. 
For example, nanomaterials, such as dendrimers,
5
 polymers,
6-7
 proteins,
8
 gold 
9
 and silica
10-11
 
nanoparticles have been applied as slowly moving carriers for Gd(III)-complexes. One of the 
most significant limitation of the currently reported nanosized T1-CAs is their large overall size 
(>100 nm) that markedly affect their in vivo distribution as they are quickly cleared by the 
reticuloendothelial system (RES). The RES is part of the immune system and consists of 
phagocytic cells like monocytes and macrophages that are located in the spleen, lymph nodes, 
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and liver Kupffer cells.
12
 The large nanoparticles are readily cleared by RES or by the 
circulating mononuclear phagocytic system (MNP), while the smaller nanoparticles, particularly 
those smaller than 50 nm, exhibit longer retention time in the bloodstream and appear more 
suitable for pursuing their accumulation in diseased tissues.
13
 For these reasons, there is still a 
great interest to develop MRI CAs based on small, monodisperse particles endowed with good 
stability and biocompatibility, site-specificity, and high relaxivity for in vivo imaging 
applications. 
Mesoporous Silica Nanoparticles (MSNs) have been suggested as excellent candidate for 
building up an attractive multifunctional platform for diagnosis and therapy thanks to their 
peculiar properties such as high surface area, large pore volume, uniform and tunable pore size, 
and facile functionalization.
14
 Currently, few MSNs-based agents have been proposed, whose 
main limitation appears associated to their overall large size and to their tendency to aggregate 
when dispersed in a physiological medium.
15
 Although a recent report has shown that the size of 
MSNs can be reduced to be smaller than 50 nm, nevertheless, the obtained nanoparticles 
resulted to aggregate.
15-16
 Therefore, a reliable large scale preparation of MSNs endowed with a 
small hydrodynamic diameter, functional groups and excellent dispersity in physiological 
aqueous conditions still remains challenging. 
Cancer is a class of diseases in which a group of cells display uncontrolled growth, and ability 
to invade other tissues.
17
 One of the hallmarks of the tumor progression is angiogenesis, i.e. the 
formation of new blood vessels, without which a tumor cannot grow beyond a few millimeters 
in diameter.
17
 The cell adhesion receptor, integrin v3, is an important player in the process of 
tumor angiogenesis and metastasis.
18
 It's also a receptor for the extracellular matrix proteins that 
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owns an exposed cyclic arginine-glycine-aspartic (RGD) tripeptide sequence.
18
 Therefore, the 
possibility of non-invasively imaging the integrin v3 expression offers a route to diagnose 
cancer and its metastasis at an early stage of the tumor growth.
18-19
 For this reason, probes 
conjugated with the RGD peptide have been suggested as efficient systems for targeting integrin 
v3 receptors.
20
 
In this work, we report the design and testing of a high r1-relaxivity, bimodal (Optical and 
MRI) targeting nanoprobe based on a multifunctional platform of fluorescein-doped and 
amino-functionalized, small sized MSNs. The macrocyclic Gd-DOTAGA 
[DOTAGA=2-(R)-2-(4,7,10-triscarboxymethyl-1,4,7,10-tetra-azacyc -lododec-1-yl) 
pentanedioic acid], which features four carboxylate donor groups and one inner-sphere water 
molecule, was used as MRI reporter (Scheme 1). The paramagnetic Gd-MSNs were further 
labeled with RGD peptides to target integrin v3 receptors. The cytotoxicity and targeting 
capability of the obtained multifunctional nanoprobes were first evaluated in vitro, in U87MG 
human glioblastoma cell line, and then further validated in vivo for targeted T1-weighted MR 
imaging of a xenografted tumor model. 
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Scheme 1. The synthetic route of the FITC-doped MSNs-NH2, followed by Gd-DOTAGA and 
RGD-conjugation for bio-applications. 
2 Results and discussion 
2.1 Synthesis and characterization of the multi-functionalized Gd-MSNs-RGD 
nanoprobe: As a general rule, large nanoparticles are preferentially filtered out by RES, 
whereas tiny nanoparticles tend to be cleared through kidneys.
21
 Therefore, it has been 
suggested that nanoparticles within the size of 10 ~ 50 nm in diameter are greatly desirable for 
in vivo applications.
22-23
 Common synthetic strategies for functionalized MSNs invariantly result 
in irreversible and extensive nanoparticle aggregation during the surfactant removal and 
post-functionalization processes.
22
 Poly(ethylene glycol)-silane (PEG-silane) has been widely 
used to control the MSNs size by terminating the silica condensation on the nanoparticle 
surface.
16, 24
 In the herein proposed procedure, a PEG-silane free, one-pot, soft-templating 
sol-gel technique was adopted to fabricate the fluorescein-doped and amino-functionalized 
MSNs (MSNs-NH2) by using cetyl-trimethylammonium bromide (CTAB) as the templating 
surfactant and triethanolamine (TEAH3) as the mineralizing agent under mild conditions. High 
quality MSN-NH2were produced at grams-scale with an overall high yield of 98 %. The size 
and morphology of the MSNs were assessed by transmission electron microscopy (TEM) as 
shown in Figure 1. The MSNs-NH2 display high monodispersity and narrow size distribution 
around 30 nm as shown in the low magnification TEM image (Figure 1a). The high 
magnification TEM image showed that the obtained MSNs were characterized by a spherical 
raspberry morphology with a well-defined structure (Figure 1b). The stock aqueous suspension 
of the amino functionalized MSNs (MSNs-NH2) appears very stable as transparent colloidal 
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solution, at concentration of 10 mg/mL in 100 mL bottle, is maintained over a long time (2-3 
months). By exposing the suspension to the light of an intense red laser path, the classical 
Tyndall effect of the colloidal solution was clearly observed (Figure 1c). MSN-NH2 were then 
further conjugated with Gd-DOTAGA, PEG1570 and the targeting ligands RGD, to yield the 
Gd-MSN-RGD that did not display any significant change in morphology or size as witnessed 
by the TEM observation (Figure 1e-f). The surface modification procedure has no negative 
effect on the solubility of the final product which exhibited strong green fluorescence under 
excitation of a portable UV (365 nm) (Figure 1d). To get more insight into the stability of the 
obtained MSNs in physiological conditions, the hydrodynamic diameters of the MSNs were 
monitored in phosphate-buffered saline (PBS) solution (pH 7.4) over a period of two months by 
dynamic light scattering (DLS) measurements (Figure 1g). The average hydrodynamic diameter 
(assessed on the basis of the intensity of the scattered light) of the MSN-NH2 resulted stable at 
33±2 nm (with a mean poly-dispersity index (PDI) of 0.028±0.003) which is slightly larger than 
the value obtained by TEM. This discrepancy is attributed to the hydration sphere of the 
nanoparticles in solution. The mean hydrodynamic diameter of the functionalized 
Gd-MSN-RGD increased to 43±3 nm (PDI 0.077±0.004) due to the protruding of the surface 
ligands in solution.  
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Figure 1. Low magnification TEM images of (a) FITC-doped MSNs-NH2 and (e) 
Gd-MSN-RGD, high magnification TEM images of (b) FITC-doped MSNs-NH2 and (f) 
Gd-MSN-RGD. The photographs demonstrate the clearly transparent colloidal solution of (c) 
FITC-doped MSNs-NH2 (10 mg/mL) and (d) Gd-MSN-RGD (3 mg/mL) and it's corresponding 
fluorescence under a portable UV lamp (365 nm) excitation. (g) Long-term colloidal stability of 
the FITC-doped MSNs-NH2 and Gd-MSN-RGD in PBS (pH 7.4, 25 
o
C), reported as variation 
of the mean hydrodynamic diameter obtained by DLS size distribution (assessed by means of 
the measured intensities). The error bars were obtained from three independent measurements. 
Based on the DLS measurements, both MSN-NH2 and Gd-MSN-RGD displayed a very good 
monodispersity. No significant size change was observed after storage for 8 weeks 
demonstrating their good colloidal stability in PBS. The surface area and the pore structures of 
the MSNs were characterized by the well-established N2 adsorption-desorption technique as 
shown in Figure 2. The isotherms of both the samples exhibit the Langmuir IV type hysteresis 
which indicates the presence of well-defined mesoporous structures (Figure 2a). Calculated on 
the basis of the Brunauer-Emmett-Teller (BET) method, the surface areas of MSN-NH2 and 
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Gd-MSN-RGD resulted to be 442 m
2
/g and 237 m
2
/g, and the pore volumes of these two 
samples were 1.01 and 0.92 cm
3
/g, respectively. By nonlocal density functional theory 
(NLDFT) calculations with the spherical-pore model,
25
 a uniform pore size distribution centered 
at 4.5 nm and 3.7 nm can be obtained for the MSN-NH2 and Gd-MSN-RGD, respectively 
(Figure 2b). We found that upon functionalizing with RGD, the surface area, pore volume and 
size of the resulting nanoparticles were smaller than those found for the parent MSN-NH2 
materials. Notably, the Gd-MSN-RGD still displayed a quite large surface area (237 m
2
/g) that 
will allow a good drug payload for future “theranostic” applications. 
 
Figure 2. N2 adsorption-desorption isotherms (a) and the corresponding pore size distribution 
(b) of MSNs-NH2 (■) and Gd-MSN-RGD (●), respectively. 
The room-temperature absorption and emission spectrum of Gd-MSN-RGD in aqueous 
solution showed the characteristic optical properties of fluorescein (Figure S1, supporting 
information). The intense fluorescence emission clearly indicated that these particles can be 
detected in fluorescence imaging. The successful surface modification of the MSNs was 
confirmed by the following characterizations. (1) In TEM images, composition analyses by 
energy dispersive X-ray (EDX) (Figure S2) and X-Ray photoelectron spectrometry (XPS) 
(Figure S3) revealed the presence of large amounts of Gd and a great increase of C and O in the 
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Gd-MSNs-RGD specimen, supporting the occurrence of a successful functionalization (Figure 
S2). (2) Both Fourier transform infrared (FTIR) spectroscopy and thermogravimetric analysis 
(TGA), before and after bio-conjugation (see Supporting Information for a detailed explanation 
- Figure S4 and S5), were investigated. The strong and broad band in the range of 1207 1047 
cm
1
and a relative weak peak at 460 cm
1
, correspond to the Si-O-Si asymmetric (νas) stretching 
vibrations arising from the SiO2 matrix. Upon reaction wtih Gd
3+
-DOTAGA, PEG and RGD, 
new peaks (at  =1546 and 1627 cm1) are observed which can be attributed to the vibration of 
imide-bond (Figure S3B). Moreover, the sharp peak at 1089 cm
1
 belongs to the C-O-C 
stretching vibration from the PEG chains. The bioconjugation also caused 19 % increase of 
weight in the TGA data, giving support to the accomplishment of surface modification.(3) The 
surface zeta-potential of MSNs-NH2 was +25.4 mV in PBS buffer at neutral pH. After the 
introduction of the negatively charged Gd-DOTAGA complexes and PEG, the value decreased 
to -25.6 mV. The further conjugation with RGD peptides, caused only a minor change in the 
zeta potential value (-23.4 mV) consistent with the introduction of about 60 µmol/g of RGD on 
the outer surface of the MSNs (Figure S6). (4) The amount of the amine-groups on the surface 
of MSNs-NH2 was identified to be 420 µmol/g (~ 2.5 -NH2 per nm
2
) by using a Fmoc-Cl 
quantification protocol.
26
 After conjugation with Gd-DOTAGA complexes, about 25 % of free 
amine-groups (105 µmol/g or 0.6 -NH2 per nm
2
) resulted available on the surface of 
Gd-MSNs-NH2 (with ~ 1.9 Gd
3+
 per nm
2
) for the reaction with PEG and RGD peptides. The 
amount of amines in the final Gd-MSNs-RGD product (with ~ 0.4 RGD molecules per nm
2
) 
was below the detection limit to indicate a good extent of conjugated PEG and RGD moieties 
(The calculation process was demonstrated in supporting information). 
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2.2 Relaxation enhancement of the Gd-MSNs-RGD nanoprobe: The longitudinal proton 
relaxivity, r1, is the measure of the efficacy of the paramagnetic complex in accelerating the 
relaxation rate of water protons. This fundamental parameter, that characterizes the properties of 
a positive MRI contrast agent, is calculated from the observed Relaxation rate constant, R1obs, by 
subtracting the diamagnetic contribution, R1d, and dividing by the actual concentration of Gd
3+
 
ions. R1d is the relaxation rate of an identical solution without the paramagnetic ions, and in our 
case coincides with the value measured for an aqueous suspension of the neat MSNs (0.37 s
-1
 at 
21.5 MHz, 25 
o
C).  
The transverse (R2) and longitudinal (R1) relaxation rates (Ri=1/Ti) of water protons as a 
function of Gd
3+
 concentration for Gd-MSNs-RGD have been measured at the fixed Larmor 
frequency of 21.5 MHz and at 25 
o
C. As shown in Figure 3a, the r1 and r2 values (slopes of the 
lines) resulted to be 37.4 and 47.2 mM
-1
s
-1
, respectively. The r1 value is ca. 7-times higher than 
that of the commercial T1 MRI contrast agents (3 - 5 mM
-1
s
-1
). The efficacy of contrast agents to 
be used as positive T1 agents is also governed by the ratio of r2/r1, and low r2/r1 ratios are 
considered to be ideal. The r2/r1 ratio of Gd-MSNs-RGD is 1.26 indicating that the MSNs 
obtained in this work could act as very efficient T1-enhancers. The high sensitivity is a primary 
requirement for molecular imaging applications as the targeting receptors are present at very 
low concentration. The T1-weighted MR-Image of a phantom of Gd-MSNs-RGD aqueous 
solutions with different Gd
3+
 concentrations was carried out on a 1-T MRI Scanner as shown in 
Figure 3b. Upon increasing the Gd
3+concentration from 0 to 540 μM, the images gradually 
became brighter. 
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Figure 3. a) Water proton longitudinal (R1) and transversal (R2) relaxation rates of 
Gd-MSNs-RGD as a function of Gd
3+
 concentration measured at 21.5 MHz and 25°C. b) 
T1-weighted MR images of Gd-MSN-RGD aqueous solutions at various concentrations of Gd
3+
 
(the black and white bar changing from black to white indicates the gradual increased in MR 
signal) obtained from 1-T MRI scanner. 
In table 1, sizes and longitudinal relaxivities of recently reported analogously functionalized 
nanoparticles are reported. The herein reported Gd-MSNs resulted to be among the most 
efficient systems when compared to analogue structures under similar conditions.  
Table 1. Comparison of longitudinal relaxivities of different Gd-complex conjugated 
nanoparticles 
Compounds size (nm) r1 
(mM
-1
s
-1
) 
field 
(MHz) 
Cell or 
in vivo 
Target ref. 
Gd(DOTAGA)-MSN 30 28/37 60/20 Both Yes This work 
Gd(DOTAGA)-MSN 25-220 20.3-79.1 20 No No 3, 10 
Gd(DOTA)-Dendrimer 142 22.4 60 in vivo No 5 
Gd(DOTA)-PLGA 150 -170 17.5 60 No No 6 
Gd(DOTA)-PLGA 140 21.7 21.5 in vivo No 7 
Gd(DOTA)-TWV 260 -640 14.6 60 in vivo Yes 8 
Gd(DTPA)-PLNP 109 6.72 50 in vivo No 27 
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Gd(HPDO3A)-PN  17 60 in vivo No 28 
Gd(DTPA)DNA-Au 30 20 60 cell No 9 
Gd(DOTA)-MSN 20-50 26.6 20 No No 3 
Gd(DTPA)-MSNR 107-535 22 20 cell No 11 
TWV: tobacco mosaic virus, PLNP: persistent luminescent nanoparticles; PN: peptide 
nanofiber; MSN: mesoporous silica nanoparticles; PLGA: poly(D,L-lactide-co-glycolide); The 
molecular structures of the Gd-complex are shown in Figure S7. 
It was recently demonstrated, that the chemical nature of the surface of functionalized MSNs 
affects the relaxometric properties of the conjugated Gd-complexes.
3, 10
 In particular, the 
presence of pendant amino groups, which are protonated at neutral pH, can affect the water 
exchange rate of the Gd-coordinated water molecule by establishing an electrostatic interaction 
with the negatively charged Gd-DOTAGA complexes. The overall result is the decrease of the 
residual negative charge that, in turn, yields a “quenching” of the relaxivity of the paramagnetic 
complex. The relaxivities of the herein synthetized Gd-MSNs-PEG and Gd-MSNs-RGD, on the 
contrary, seem not to be affected by the presence of free amino groups, as their values are 
higher than that previously reported for analogous NH2 functionalized MSNs (20.3 mM
-1
s
-1
 at 
20 MHz and 310 K) and very close to that observed upon transformation of the amino 
functionalities into neutral amide groups (37.8 mM
-1
s
-1
 at 20 MHz and 310 K).
10
 Likely, the 
observed behavior has to be accounted for the considerably lower density of -NH2 
functionalization of the MSNs presented in our work (<0.1 mmol/g ) with respect to that of the 
MSNs reported in reference 3 and 10 (2.8 mmol/g). 
For a thorough relaxometric characterization of the two probes, the nuclear magnetic 
relaxation dispersion (NMRD) profiles of Gd-MSNs-PEG and Gd-MSNs-RGD were measured 
over the frequency range of 0.1 – 70 MHz at 25 oC (Figure 4). The NMRD profiles of the two 
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probes were almost identical with a relaxivity peak centered on 21 MHz, typical of slowly 
tumbling systems. The experimental data were fitted to the Solomon–Bloembergen–Morgan 
equations (4 – 70 MHz), modified by incorporating the Lipari–Szabo approach for a better 
definition of the rotational dynamics (Table 2), i.e. the spectral density function is governed by 
two terms: one is related to the global motion of the nanoparticles (τRG) and the other to the 
local rotation of the complex around the axis of the linker (τRl), respectively. The obtained 
correlation times are related by the factor S
2
 (0 ≤ S2 ≤ 1) which describes the degree of spatial 
restriction: if the motion of the Gd-complex is totally independent from that of the nanoparticle, 
S
2
 = 0, while if the Gd complex is completely immobilized on the nanoparticles, then S
2
 = 1. 
Considering the slow global tumbling of the nanosized systems, the RG was fixed to 100 s.
10
 
The small S
2
 (0.354 and 0.346) and short Rl (1.17 and 0.992 ns) values indicated the occurrence 
of a high degree of local mobility. By assuming that the exchange with the bulk solvent is not 
significantly affected by the structural constrain resulting from the conjugation of the metal 
complex to the MSNs surface, data were fitted by fixing the residence lifetime of the 
coordinated water (M) to that of the parent Gd-DOTA complex (0.24 μs).
29
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Figure 4. The magnetic-field dependence of the relaxivity (r1) measured over an extended range 
of magnetic field strengths (from 0.01 to 70 MHz). The nuclear magnetic relaxation dispersion 
(NMRD) profiles were obtained for the aqueous suspensions of Gd-MSN-RGD(■) and 
Gd-MSNs-PEG (●) at 25 oC and normalized to 1mM concentration of Gd3+.  
Table 2. Summary of the best-fitting values of key parameters obtained from the analysis of 
NMRD profiles reported in Figure 4.
a
 
Compounds r1 (mM
-1
s
-1
) RG (ms)* Rl (ns) M (μs)* S
2
 
Gd-MSNs-RGD 37.60 0.1 1.17 0.24 0.354 
Gd-MSNs-PEG 36.33 0.1 0.992 0.24 0.346 
a
 The distance of the proton of the coordinated water molecule from the metal ion (rGd-H) was 
fixed to 3.0 Å. * These values were kept fixed during the fitting procedure. 
2.3 Cytotoxicity and cell imaging: The in vitro cytotoxicity of Gd-MSNs-RGD was assessed 
on U87MG cells by using the Cell Titer-Blue
®
 cell viability Assay (Figure 5). The viability of 
the untreated cells was used as the control (100 %). No significant decrease in the cell viability 
(> 93%) was observed upon incubating the U87MG cells with Gd-MSNs-RGD (concentration: 
100 to 800 µg/mL) at 37 
o
C for 6, 12 or 24 h. Notably, the cell viability was still higher than 90 
% even after 24 h incubation with 800 µg/mL of the probes, a dose which is much higher than 
that used for in vitro and in vivo applications.  
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Figure 5. Cell viability of a human glioblastoma U87MG cell line incubated with different 
concentrations of Gd-MSNs-RGD for 6, 12 and 24 h, respectively. 
The integrin αvβ3 binding affinity of RGD-conjugated MSNs was first evaluated by laser 
confocal scanning microscopy (LCSM) (Figure 6). An intense green fluorescence signal was 
observed on the integrin-positive U87MG cells upon applying the 488 nm laser excitation. To 
establish the localization of nanoprobes, the nuclei of the U87MG cells were stained with the 
blue fluorescent dye DAPI. The image overlaying FITC and DAPI emissions shows that 
Gd-MSNs-RGD distributes either at the cell surface and inside the cells, likely internalized into 
endosomes as it is well established that these receptors undergo receptor-mediated 
endocytosis.
18
 For comparison, the control experiment of CLSM imaging was carried out by 
incubating Gd-MSNs-PEG (no RGD ligands) with U87MG cells under identical conditions. 
Negligible signals were detected at the U87MG cells due to the lack of specific integrin αv3 
targeting ligands. In addition, binding of the nanoprobes to U87MG cells was effectively 
blocked in presence of 2 µM free RGD before the incubation with Gd-MSNs-RGD. Only a very 
weak fluorescence could be detected which is ascribed to the passive uptake of nanoparticles. 
17 
 
 
Figure 6. Confocal laser scanning microscopy (CLSM) images of U87MG cells incubated with 
Gd-MSNs-RGD (target group) and Gd-MSNs-PEG (control group) at 200 μg/mL concentration 
at 37 
o
C for 4 h (scale bar = 75 mm). The blocking experiment was carried out by incubating 
U87-MG cells with Gd-MSNs-RGD in the presence of an excess of free RGD (2 µM). 
 
Furthermore, to evaluate the feasibility of using the Gd-MSNs-RGD nanoprobes to detect 
cancer cells by MR imaging, the MR signal intensity of U87MG cells incubated with both 
Gd-MSNs-PEG (as control RGD-) and Gd-MSNs-RGD (as target RGD+) at different Gd 
concentrations (0, 5, 10, 15, and 20 µM) were acquired on a 7T MRI scanner (Figure 7a). The 
Gd-MSNs-RGD highlighted the U87MG cells upon increasing Gd concentration. The MR 
signal enhancement is much greater than that of the control group. The amount of Gd uptaken 
by U87MG cells was quantified by inductively coupled plasma–mass spectrometry (ICP-MS) 
and Bradford protein assay (Figure 7b). The amount of Gd
3+ 
uptaken in targeted cells is 0.92, 
1.4, 2.8, and 4.4 nmol Gd
3+
 per mg of protein, respectively. Whereas, the Gd
3+
 uptake in control 
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group was much lower as 0.15, 0.31, 0.63, and 1.4 nmol Gd
3+
 per mg of protein were measured, 
respectively. At low particle’s concentrations, the uptake from targeted group is 6 fold higher 
than that of the control group. v3 receptors are known to internalize quite efficiently 
RGD-functionalized substrates, thus, we surmise that most of the RGD-functionalized MSNs 
have been internalized by receptor-mediated endocytosis.  From both fluorescence and MRI 
cell-staining experiments, it can be concluded that Gd-MSNs-RGD exhibits a good integrin 
αv3-specific binding capability in vitro.  
 
Figure 7. a) T1-weighted MR images (at 7T) of U87MG cells incubated with Gd-MSNs-PEG 
and Gd-MSN-RGD for 3 h at 37 
o
C. b) Results of the quantitative analysis of Gd
3+
 entrapped 
into the U87MG cells measured by ICP-MS and Bradford protein assay after MR imaging. 
2.4 Targeted in vivo MR imaging and ex vivo biodistribution studies:  
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Figure 8. a) In vivo T1-weighted MR images of subcutaneous U87MG glioblastoma (over 
expressing αv3) and A431 (low expressing αv3) tumor-bearing athymic nude mice (n = 3) 
obtained before and after 1h, 6h and 24 h the intravenous injection of Gd-MSN-RGD (target 
group) and Gd-MSNs-PEG(control group). The red spots correspond to the signal enhanced 
pixels. Quantitative analysis of signal intensity enchantment of b) target group and c) control 
group MR images. d) Ex vivo fluorescence images of main organs resected after completion the 
MRI scanning (24 h post-injection). 
The in vivo targeting capability of Gd-MSNs-RGD towards αv3 integrin receptors has been 
assessed by acquiring signal intensity enhancements in T1-weigthed MR imaging at different 
time points (1, 6 and 24 h) post injection. Athymic nude mice (n = 3) bearing two xenografted 
tumors were used, namely the human malignant glioma U87MG on the left shoulder (αv3 
overexpressing tumor) and the human epidermal carcinoma A431 on the right shoulder (as 
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control), respectively. The Gd-MSNs-RGD were used as targeting nanoprobes while 
Gd-MSNs-PEG (without RGD vectors) were used as control probes. The T1-weighted MR 
images of U87MG tumor showed significant signal  enhancements as compared with the 
images of A431 tumor upon tail vein administration of Gd-MSNs-RGD (at the dose of 0.021 
mmol/kg) after 1 and 6 h (Figure 8a). The fast accumulation of the targeting nanoprobes at the 
U87MG tumor site could be attributed to their small size. The signal to noise enhancement of 
the T1-MR image in U87MG tumor was about 2.3 times higher than that in A431 tumor (Figure 
8b). At 24 h time point, the signal enhancement in U87MG tumor was decreased and this may 
be due to the biodegradation and clearance of the nanoprobes from the body. The targeting 
specificity was further checked, by using Gd-MSNs-PEG (i.e. without RGD ligands) as negative 
control. In this experiment, nearly no contrast enhancement in both tumors was observed. These 
results indicated that the Gd-MSNs-RGD nanoprobes display an efficient active targeting ability 
towards the integrin αv3 receptors overexpressed in U87MG tumor. A relatively large amount 
of nanoprobes accumulates in liver and spleen, with both targeted and control probes. The 
accumulation in liver and spleen is expected for nanoparticles, which are taken up from 
circulation mainly through the RES. It should be noted that the wash-out of the targeted 
nanoprobes in these organs was not as fast as that in the control group (Figure 8b-c). This could 
be caused by the normal expression of αv3 integrin in these organs according to previous 
reports.
18, 20
 To double confirm the imaging results and trace the biodistribution of the 
nanoprobes in mice, the ex vivo fluorescence images of major organs (tumor, liver, spleen, 
kidney,) were examined using fluorescence microscopy (Figure 8d). Similar to the in vivo 
images, significant intensive emissions from the nanoprobes were observed in U87MG tumor of 
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the targeted group, suggesting highly efficient targeting ability of the Gd-MSNs-RGD. 
Collectively, the above observations demonstrated that the Gd-MSNs-RGD could be used as a 
positive MRI contrast agents for in vivo imaging applications. 
3 Experimental 
3.1 Materials: Chemicals and materials:1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride salt (EDC), N-hydroxysulfosuccinimide (Sulfo-NHS), fluorescein-5- 
isothiocyanate (FITC), (3-Aminopropyl)trimethoxysilane (APTES), hexadecyltrimethyl- 
ammonium bromide (CTAB), triethanolamine (TEAH3), O-[N-(3-Maleimidopropionyl)- 
aminoethyl]-O′-[3-(N- succinimi-dyloxy)-3-oxopropyl] heptacosaethylene glycol ≥ 90% 
(Mal-PEG27-NHS ester),  Dimethylformamide (DMF), dimethyl sulfoxide (DMSO) and all the 
solvents were purchased from Sigma−Aldrich and used without further purification. 
4′,6-diamidino-2- phenylindole (DAPI) was purchased from Life Technologies, Inc. The cyclic 
5mer cyclo(-Arg-Gly-Asp-d-Phe-Lys-) (c(RGDfK)) peptide with the thioether group at the 
lysine residue was purchased from CS Bio Co. 2-(R)-2-(4,7,10-triscarboxy- 
methyl-1,4,7,10-tetraazacyclododec-1-yl) pentanedioic acid = DOTAGA was synthesized, as 
reported previously.
30
 Water used in all experiments was purified using a Milli-Q Plus 185 
water purification system (Millipore, Bedford, MA) with resistivity higher than 18 MΩcm. 
3.2 Synthesis of FITC-doped and amino-functionalized small size MSNs (MSNs-NH2): The 
The synthesis of FITC-doped MSNs-NH2 has been carried out according to a slight 
modification of a previous report.
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Firstly, 12 mg of FITC were conjugated to APTES (2 mL in 1 mL dried DMF). The mixture 
was stirred overnight under dark to yield FITC-silane in APTES solution (the obtained molar 
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ratio of FITC-silane to APTES is 1: 370). Then, a mixture of 2.1 mmol of CTAB, 0.91 mmol of 
TEAH3 and 100 mL of deionized water was stirred at 80 
o
C for 1 hour, and 4 mL of TEOS was 
quickly added into the surfactant solution and stirred at 12000 rmp for 30 min. Then, 1.5 mmol 
of FITC-silane in APTES was added dropwise and the reaction was stirred at 60 °C for other 3.5 
h. Afterwards, the reaction solution was cooled to room temperature (R.T.) and then transferred 
into a dialysis membrane tube (Pierce, Molecular Weight Cut Off 10,000) where it was dialyzed 
in 500 ml acid solution composed by water, ethanol and acetic acid (volume ratio 1:1:0.01) for 
24 h to extract CTAB out of the pores of the silica nanoparticles. This process was repeated 
three times. The solution was then dialyzed in 2 L D.I.-water for 4 h. This process was repeated 
two times. The final colloidal product was collected and concentrated by evaporating water at 
room temperature (98 % yield). The reaction volume of this protocol can be varied from 10 mL 
to several hundred milliliters according to the output requirement. 
3.3 Functionalization of MSNs-NH2 with Gd-DOTAGA and RGD ligands 
(Gd-MSNs-RGD): Firstly, the free carboxyl group of Gd-DOTAGA complex was activated 
with EDC and Sulfo-NHS (with a molar ratio of -COOH/EDC/Sulfo-NHS = 1:5:8) at R.T. for 4 
h. Then, 20 mg of MSNs-NH2 (10.2 µmol in terms of -NH2 groups) in 3 mL DMSO solution 
were added into the activated Gd-DOTAGA solution (with a molar ratio of -NH2/-COOH = 
1:3), the mixture was stirred for 6 h at R.T. The product was transferred into a dialysis 
membrane tube and dialyzed against 1 L of water for 3 times and dispersed in 2 mL of PBS 
after being concentrated by ultrafiltration spin columns (Vivaspin, Molecular Weight Cut Off 
10,000). Subsequently, 1 mmol of Mal-PEG-NHS was added into the above PBS solution and 
stirred for 2 h at R.T., then, 2 mmol of thiolated c(RGDfK) peptide was added and stirred for 4 
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h. For the nanoprobes used as control (Gd-MSNs-PEG), an excess of ethanethiol (instead of 
RGD) was added to the solution to block the maleimide group of PEG. The final product was 
purified by dialysis in water, concentrated and stored in 2 mL PBS solution for further use. 
3.4 Particles characterization： Size and morphology of the MSNs were observed by a 
JEOL-2100 transmission electron microscope (TEM) equipped with the energy-dispersive 
X-ray spectrum. Fourier transform infrared (FTIR) spectra were performed using a Nicolet 
Avatar 370 with KBr pellets. The X-Ray photoelectron Spectromete (XPS) experiments were 
carried out on a RBD upgraded PHI-5000C ESCA system (Perkin Elmer) with Al Kα radiation 
(hν = 1486.6 eV). The amount of surfactant present on the surface of MSNs was quantitatively 
measured by thermogravimetric analysis (TGA) curves which were recorded on a DTG-60H 
(Shimadzu) at a heating rate of 10 
o
C/min. The UV-vis spectra and fluorescence spectra were 
recorded by using the Olis Globalworks Cary 14 UV–vis absorption spectrophotometer and 
HORIBA Nanolog fluorimeter, respectively. The hydrated mean diameter and surface potential 
of the MSNs samples were determined by means of dynamic light scattering (DLS) Malvern 
Zetasizer 3000HS (Malvern, U.K.). 
3.5 Relaxivity measurements and in vitro MRI of Gd-MSNs-RGD aqueous suspensions： 
The Proton Nuclear Magnetic Relaxation Dispersion (NMRD) 1/T1 Profiles data were measured 
at 25 °C over a continuum of magnetic field strengths from 0.00024 to 0.47 T (corresponding to 
0.01-20 MHz proton Larmor Frequency) on a Stelar field-cycling relaxometer (Stelar, Mede, 
Italy), under complete computer control with an absolute uncertainty less than 1%. Data points 
from 0.5 T (21.5 MHz) to 1.7 T (70 MHz) were collected on a Spinmaster spectrometer (Stelar, 
Mede, Italy) working at variable fields. The concentration of Gd
3+
 of the samples was 
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determined by the following protocol: 100 μL of the samples were treated with 100 μL HCl 37 
% in sealed vials at 120 °C overnight in order to destroy the Gd-complexes and obtain Gd
3+
 
aqua-ion. The R1 of these solutions was measured at 21.5 MHz and 25 °C. The Gd
3+
 
concentration was calculated from a calibration curve obtained by using standard solutions of 
GdCl3.
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MR images of the phantom of Gd-MSNs-RGD aqueous solutions at different Gd
3+
 
concentrations (0 ~ 540 μM) were acquired on Aspect M2-High Performance 1T MRI Scanner 
(Aspect Imaging, Israel) by using a T1-weighted Spin-Echo imaging protocol (TR/TE/NEX 
=100:13:12; FOV = 24mm). 
3.6 Cell culture and cytotoxicity test：U87MG cell line is a glioblastoma, astrocytoma cell 
line derived from human malignant gliomas. U87MG cells were cultured by growing cells in 
EMEM (Euroclone-Lonza) + 10% fetal bovine serum (Euroclone-Lonza) + 100 units/ml 
penicillin +100 μg/ml streptomycin + 2mM Glutamine + 1% Non Essential Amino Acids 
(NEAA) + 1mM Sodium Pyruvate (NaP) + 5% CO2 at 37 
o
C. The cell viability was assessed by 
standard CellTiter-Blue® Cell Viability Assay Protocol. 5×10
4
 cells/well was seeded into 
96-well assay plates in culture medium. The cells were incubated with Gd-MSNs-RGD with 
different concentrations (0, 100, 200, 300, 500 and 800 μg/mL) for 6, 12 and 24 h at 37 oC 
under 5 % CO2. To minimize the test error, each concentration at each time point was measured 
in triplicate. Wells without cells were used as the negative control to determine background 
fluorescence. Thereafter, 20 μL/well of Cell Titer-Blue® Reagent were added and the final 
volume brought to 120 μL, shaked for 10 seconds and kept on incubation from 2 to 4 hours. The 
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fluorescence emission intensity of the samples were recorded by fluorimeter at λem = 590 nm 
(λex = 560 nm). 
3.7 In vitro fluorescence and MR imaging uptake experiments in U87MG cells: For the in 
vitro targeting uptake experiments, about 2.5 × 10
5 
U87MG cells were seeded in 6 cm diameter 
dishes. For fluorescence imaging, the cells were incubated with Gd-MSNs-RGD as targeting 
probes and Gd-MSNs-PEG as control at the concentration of 200 μg/mL, at 37 °C for 4 h. 
Fluorescence imaging was performed on the Leica TCS SP5 Ⅱ laser confocal scanning 
microscopy system. A 60× oil-immersion objective lens was used. Excitation of DAPI was 
carried out with a semiconductor laser at 405 nm, and its emission was collected at 460±20 nm. 
For FITC images, λex = 488 nm and λem = 500–560 nm (scale bars = 75 μm) conditions were 
used. For MR imaging, the cells were incubated with Gd-MSNs-RGD and Gd-MSNs-PEG, 
respectively, at different Gd concentrations (5-20 μM) for 3 h at 37 °C. At the end of the 
incubation, cells were washed three times with 5 mL of ice-cold PBS, detached with 
trypsin/EDTA, and transferred into falcon tubes. MR images of cell pellets were acquired on a 
Bruker Avance300 (7T) instrument equipped with a micro-imaging probe. MR images were 
obtained by using a standard T1-weighted multi-slice multi-echo sequence (TR/TE/NEX = 
200:3.3:16, field of view = 1.2 cm, one slice = 1 mm). After imaging, the cell samples were 
collected and sonicated at 30% of power for 30 s in ice, and the total protein content was 
measured by the Bradford assay by using bovine serum albumin as standard (Biorad, Hercules, 
CA, USA).
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 Next, the reset cell samples were digested with concentrated HNO3 (70%, 1 mL) 
under microwave heating (Milestone MicroSYNTH Microwave labstation). The Gd content in 
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the cell samples was determined by using inductively coupled plasma mass spectrometry 
(ICP-MS; element-2; Thermo-Finnigan, Rodano (MI), Italy). 
3.8 Animal model: Balb/C nude mice (aged 6 weeks and weighted 18 - 22 g) were purchased 
from Harlan Laboratories. Handling and all manipulations were carried out in accordance with 
European Community guidelines, and all the experiments were approved by the Ethical 
Committee of the University of Turin. A suspension of 2  106 A431  cells in 0.1 mL DMEM 
medium without serum was subcutaneously injected in right flank of each female mouse. After 
10 days, a suspension of 5  106 U87MG cells in 0.1 mL EMEM medium was subcutaneously 
injected in the left flank of the same female mouse. When both the tumors reached 0.4-0.6 cm in 
diameter, the tumour bearing mice were imaged. 
3.9 In vivo MRI: In vivo MRI experiments with Gd-MSNs-PEG and Gd-MSNs-RGD were 
carried out on U87MG and A431 tumor xenografts in Balb/C mice (n = 6) with a 1T scanner 
(Bruker, Icon Instrument). The mice were anesthetized with isofluorane and placed in cradle 
with an infusion line placed in the tail vein for the nanoprobes administration. Each nanoprobe 
suspension was administered at the dose of 0.021 mmol/kg of Gd
3+
. During measurements, 
respiration was monitored with a sensor connected to an ECG/respiratory unit. 
After localization of the tumor with a T2-weighted scan with spin–echo sequence (TR/TE = 
3000/60 ms, number of averages (NA) = 4), serial T1-weighted MR scans with multi-slice 
spin-echo sequence (TR/TE = 380/14 ms, number of averages (NA) = 4), were collected before 
the nanoprobes were intravenously injected and after 1, 6 and 24 hours. For the image analysis, 
the T1 Contrast-to-Noise Ratio (CNR(T1)) was measured as follows: 
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Where SI(A) is the MRI signal intensity of a given ROI, SI(B) is the signal from the background 
and SDV(B) is the standard deviation of the signal noise of background. Values reported are 
expressed as CNR(T1) %, which correlates CNR(T1) POST-contrast to the corresponding 
pre-contrast value. 
3.10 Ex vivo Fluorescence Microscopy Analysis: After in vivo MR imaging, the 
fluorescence microscopy analysis of the major organs of both control and target groups were 
carried out by the Fluorescence microscope AXIO ZOOM.VI16 (ZEISS, Germany) to 
investigate the biodistribution of the injected particles  (FITC excitation 470±20 nm, emission 
525±25 nm, Exposition 170 ms, Gain 120, Zoom 4X ). A control mouse without injection of 
any contrast agent was used for the analogous fluorescence images as blank. 
4 Conclusion 
In summary, a RGD-labeled multifunctional nanoprobe targeting integrin αV3 receptors 
based on modified MSNs has been synthesized and tested both in vitro (fluorescence/MRI) and 
in vivo (MRI). The small size (~ 30 nm) and good monodispersity (PDI < 0.05) endow these 
MSNs with excellent physiological stability and biocompatibility. Further surface modification 
endows them with high relaxivity (37.6 mM
-1
s
-1
 at 21.5 MHz) and targeting capability. The 
application of integrin αv3 targeted Gd-MSNs-RGD for high sensitive multifunctional imaging 
study, from the cellular scale to small-animal whole-body evaluation, has been demonstrated 
This study may open new perspectives for the design of high sensitivity multimodal 
nanotherapeutics for application in cancer diagnosis and management as well as in 
imaging-guided surgery and therapy. 
Supporting information: 
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Absorption and emission spectra, Energy dispersive x-ray analysis (EDXA) and XPS spectra, 
TGA, zeta-potential and the molecular structures of the Gd-complexes which have been cited. 
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